TABLE 2
Results for HGG Patients
| Patient no. | Weight (kg) | Aadm (MBq) | ν*† (Hz) | νNT*† (Hz) |  *† (s) |  * (MBq/kg) | Diagnosis | Previous treatment |
| G01 | 97 | 246 | 16.5 | 1.4 | 0.5 | 1.5 | HGG | S/RT/CT/PRRT |
| G02 | 68 | 223 | 5.2 | 1.1 | 2.6 | 8.5 | HGG | RT/CT/B |
| G03 | 80 | 152 | 9.6 | 1.9 | 1.4 | 4.3 | HGG | S/RT/CT |
| G04 | 93 | 198 | 22.4 | 3.7 | 0.6 | 1.8 | HGG | S/RT/CT/PRRT |
| G05 | 90 | 192 | 4.6 | 2.0 | 7.4 | 23.6 | HGG | S/RT/CT/PRRT |
| G06 | 60 | 185 | 4.4 | 1.6 | 5.8 | 20.0 | HGG | S/RT/CT |
| G07 | 63 | 194 | 4.8 | 1.7 | 5.1 | 17.6 | HGG | S/RT/CT |
| G08 | 70 | 266 | 2.1 | 0.8 | — | 40.0 | HGG | RT/CT |
| G09 | 85 | 255 | 3.7 | 1.1 | 5.3 | 17.6 | HGG | S/RT/CT |
| G10 | 80 | 224 | 2.2 | 1.6 | — | — | Oligodendroglioma | S/RT/CT/I |
| G11 | 70 | 234 | 5.1 | 2.0 | 5.5 | 18.8 | HGG | RT/CT |
| G12 | 15 | 38 | 5.0 | 2.0 | 5.9 | 18.8 | Pontine glioma | RT/CT/PRRT |
↵* Data assume 12 h between administration of 90Y and surgery.
↵† Estimations assume that reference activity Aref = 3 MBq/kg is administered.
Nles. = number of lesions; Aadm = administered activity; ν = signal rate expected on probe in each lesion; νNT = nontumor rate expected on probe in each lesion;
= time needed to identify a 0.1-mL residual; 
= the minimum activity that needs to be administered to have 
; S = surgery; RT = radiotherapy; CT = chemotherapy; PRRT = peptide receptor radionuclide therapy; B = bevacizumab; I = immunotherapy.